drugset / Trial / NCT01514825

A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects

NCT01514825

Phase 1 Completed 36 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to evaluate the safety and plasma concentration change of YM150 after repeated administration to healthy elderly male and female subjects.

Timeline

Start
2006-11
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject darexaban Small molecule Oral

Indications

No indication recorded.